New scan could sharpen prostate cancer detection
NCT ID NCT07485881
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will compare a newer imaging method called 18F-PSMA PET/CT with the standard CT scan for prostate cancer patients. The goal is to see if the new scan is better at finding cancer initially, checking how well treatment is working, and detecting cancer that has come back. About 59 patients will be enrolled, and the results could help doctors make more informed decisions about treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-PSMA (a radioactive tracer for PET imaging)
What this could lead to
If this works, it could show that 18F-PSMA PET/CT is better than standard CT at detecting and monitoring prostate cancer, leading to more accurate staging and treatment decisions.
What could go wrong
This is a small, early-stage study with only 59 participants, so results may not apply to all patients. The new scan may not prove significantly better than CT, and there are risks like claustrophobia or radiation exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••